August 3, 2022. The Court in the Puma Biotechnology
securities matter (Central District of California) approved a class action
settlement in the amount of $54.2 million. The settlement followed a 2019
federal jury trial that resulted in the jury finding Puma Biotechnology guilty
of securities fraud. Plaintiffs alleged that Puma Biotechnology made false and
misleading statements regarding the results of the ExteNET trial and the
efficacy and safety of the neratinib drug. Professor Steven Feinstein of Babson College and Crowninshield
Financial Research provided expert reports on market efficiency, loss causation
and damages, and provided testimony at trial.
Read more on this case at Stanford Securities Class Action Clearinghouse
Tagged settlement